Many members of the drug class quinazoline were reported to target tyrosine kinases as the case of cediranib (VEGFR/PDGFR), sunitinib malate (VEGFR/PDGFR/c-KIT/FLT-3), and the anti-CRC drug vatalinib (VEGFR-1/VEGFR-2). The gene discussed is KDR; the disease is colorectal carcinoma.